Endovastec(SH:688016) 光大证券研究·2025-12-20 00:04Group 1 - The company's domestic business is progressing steadily, while its international subsidiary Lombard is expected to turn profitable this year. The improvement in profitability is attributed to enhanced production efficiency and a domestic raw material utilization rate exceeding 85%, leading to an anticipated overall gross margin recovery to over 70% for the year [4]. - In Q3 2025, the company's revenue grew by 64.68% year-on-year, primarily due to a low base effect from the previous year when major products were impacted by price governance. However, profit declined year-on-year mainly due to product price adjustments. The overseas business has become a significant growth engine, with revenue growth exceeding 65% in the first three quarters, now accounting for 18% of total revenue, and the overall gross margin for overseas operations has improved to 50% [4]. Group 2 - The company is continuously optimizing its R&D investment structure to enhance the R&D output ratio. Significant progress has been made across various product pipelines, providing momentum for medium to long-term development. The Hector thoracic aortic multi-branch stent system successfully completed the first pre-market clinical implantation in November. Other products, such as the Aegis II abdominal aortic stent system and IBD iliac branch stent, are progressing as planned. Key peripheral products are expected to receive approval for market launch within the next year [5].